SM
TPST icon

Sabby Management’s Tempest Therapeutics TPST Stock Holding History

Sabby Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1
Closed -$1.87M – 368
2015
Q3 		$1.87M Buy
+1
New +$67.3K 0.08% 165
2015
Q2 		– Hold
0
– – – 252

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Sabby Management's TPST Position: Q2 2026 in Review

Sabby Management increased its Tempest Therapeutics (TPST) stake by 2,763% in Q2 2026, buying an estimated $814K and bringing the position to 511,286 shares worth $568K. The position accounts for 0.51% of the portfolio, ranked #12.

Sabby Management first reported a position in TPST in Q3 2013 and has held it in 21 quarters since. The position peaked at $10.3M in Q2 2015. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • Sabby Management held 511,286 shares of Tempest Therapeutics worth $568K as of Q2 2026.
  • Sabby Management bought 493,430 Tempest Therapeutics shares in Q2 2026, an estimated $814K.
  • Tempest Therapeutics made up 0.51% of Sabby Management's portfolio in Q2 2026, its #12 holding.
  • Sabby Management first reported a position in Tempest Therapeutics in Q3 2013 and has held it in 21 quarters since.
  • Sabby Management's Tempest Therapeutics position peaked at $10.3M in Q2 2015.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.